Clinical observation on effect of calcium dobesilate combined with losartan potassium on proteinuria in pa-tients with diabetic nephropathy

JIN Ming-wei

doi:10.3969/j.issn.1674-3806.2015.02.14

Abstract：Objective To explore the effect of treating diabetic nephropathy(DN) by calcium dobesilate combined with losartan potassium on proteinuria in patients with DN, and its safety.Methods Seventy-two patients with DN who were treated were collected from Mar.2011 to Aug.2013.According to draw method,they were divided into losartan potassium group and combination group, 36 cases in each group.Losartan potassium group was orally treated with losartan potassium 50 mg/d on basis of conventional treatment.The combination group was orally treated with calcium dobesilate capsules,500 mg/time,3 times a day,on basis of losartan potassium group,the treatment course was two months.The change in serum creatinine( Cr) , blood urea nitrogen( BUN) , 24 hours′urinary albumin-excretion rate( UAER) before and after treatment and the occurrence of adverse reactions during treatment were com-pared between the two groups.Results The Cr, BUN, 24 hours′UAER before treatment had no significant differ-ence between the two groups;after treatment,the Cr,BUN had no significant difference from those before treatment in the two groups(P>0.05), the 24 hours′UAER was significantly lower than that before treatment in the two groups (P<0.01), and the 24 hours′UAER in combination group were significantly lower than that in losartan potassium group(P<0.01).No obvious adverse reaction was found in the two groups.Conclusion Treating DN with losartan potassium combined with calcium dobesilate can reduce urinary protein excretion, decrease UAER, protect renal function, delay DN progress.It is worthy of clinical reference.